Precigen reports Q2 2026 net income of $20.1M; PAPZIMEOS revenue $53.1M, more than double prior quarter

PRECIGEN, INC.

PAPZIMEOS net revenue $53.1M in Q2 2026, more than double prior quarter; total revenues $55.0M.
Net income $20.1M ($0.06 basic EPS) vs net loss $26.6M ($0.09 loss) in Q2 2025.
Cash, equivalents, and investments $38.7M as of June 30, 2026; expects cash flow break-even by end of 2026.
FDA granted PAPZIMEOS seven-year market exclusivity; patient hub enrollment over 500 patients.
MAA for PAPZIMEOS under review by EMA; PRGN-2009 pipeline update expected by year-end.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.